Skip to main content

Home/ Medicine & Healthcare/ Group items tagged clinical-trials

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
avivajazz jazzaviva

MEGA: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese - 0 views

www.medscape.com/...518573

cardiology cardiovascular medical medicine preventive cardiology prevastatin women statins prevention preventive over-the-counter MEGA clinical.trials untagged aviva.gabriel

shared by avivajazz jazzaviva on 14 Oct 09 - Cached
  • avivajazz jazzaviva on 14 Oct 09
     
    Rader also believes that the MEGA trial raises important questions about just how widespread the use of statin therapy should be in primary prevention...reignite discussion on over-the-counter low-dose statins.
avivajazz jazzaviva

Management of superficial basal cell carcinoma: focus on imiquimod ~ 2009 - 0 views

www.ncbi.nlm.nih.gov/...ccid-2-065.pdf

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies free fulltext freefulltext pdf

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Raasch B. Clinical, Cosmetic and Investigational Dermatology. 9 June 2009.  There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides  outcomes only marginally less satisfactory t
avivajazz jazzaviva

Management of superficial basal cell carcinoma: focus on imiquimod - 0 views

www.ncbi.nlm.nih.gov/...PMC3047930

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides outcomes only marginally less satisfactory than surgery. There would be a place for imiquimod in treating patients with frequent multiple primary lesions when access to surgery is difficult or where clinical judgment may be influenced by patient factors as reported in some of the studies, eg, where patients may have contraindications to surgery.  It was noted that if recurrences occurred in this study they mostly occurred during the first 9 months after the end of treatment. The initial response was therefore predictive of long-term outcome so these authors recommend and encourage continued monitoring of skin lesions.
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinoma following successful treatment with... - 0 views

www.jle.com/...article.phtml

recurrence rate recurrences recurrence-rate BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies free fulltext free

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%. 
avivajazz jazzaviva

Imiquimod 5% cream for the treatment of superficia... [J Am Acad Dermatol. 2004] - PubM... - 0 views

www.ncbi.nlm.nih.gov/...15097956

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Composite clearance rates (combined clinical and histological assessments) for the 5 and 7x/week imiquimod groups were 75% and 73%, respectively. Histological clearance rates for the 5 and 7x/week imiquimod groups were 82% and 79%, respectively. Increasing severity of erythema, erosion, and scabbing/crusting was associated with higher clearance rates. CONCLUSION: Imiquimod appears to be safe and effective for the treatment of sBCC when compared with vehicle cream. The difference in clearance rates between the two imiquimod dosing groups was not significant. The 5x/week regimen is recommended.
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2005 Sep-Oct] - ... - 0 views

www.ncbi.nlm.nih.gov/...16172048

recurrence rate recurrences recurrence-rate BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%.
avivajazz jazzaviva

Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week p... - 0 views

www.ncbi.nlm.nih.gov/...19646136

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies 1-year 2-year followup

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Clinical clearance rate at 1 and 2 years were 89% and 85%, respectively.
avivajazz jazzaviva

Has imiquimod 5% cream a role in the management of... [Eur J Dermatol. 2009 Sep-Oct] - ... - 0 views

www.ncbi.nlm.nih.gov/...19527989

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies recurrent refractory 3-year followup

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
avivajazz jazzaviva

Two-year interim results from a 5-year study evalu... [Australas J Dermatol. 2006] - Pu... - 0 views

www.ncbi.nlm.nih.gov/...17034468

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies 5-year results

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing increases local skin reactions.
avivajazz jazzaviva

Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream | Alessi SS, et al | CLIN... - 0 views

www.ncbi.nlm.nih.gov/...cln_64p961.pdf

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies pdf

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
    • avivajazz jazzaviva
      avivajazz jazzaviva on 24 Jul 11
       
      For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
  • avivajazz jazzaviva on 24 Jul 11
     
    For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
avivajazz jazzaviva

Treatment of cutaneous tumors with topical 5% imiq... [Clinics (Sao Paulo). 2009] - Pub... - 0 views

www.ncbi.nlm.nih.gov/...19841702

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    For patients without comorbidities, the overall cure rate was 73%. For these patients, the cure rates were 85.7% for superficial and nodular BCC, 88% for superficial BCC, 57% for Bowen's disease, 50% for nodular BCC, and 50% for aggressive BCC.
‹ Previous 21 - 40 of 43 Next ›
Showing 20▼ items per page